Welcome to our dedicated page for Haemonetics Corporation news (Ticker: HAE), a resource for investors and traders seeking the latest updates and insights on Haemonetics Corporation stock.
Haemonetics Corporation (NYSE: HAE) is a global leader in blood management solutions, dedicated to improving patient care and reducing healthcare costs. The company offers a comprehensive portfolio of integrated devices, information management systems, and consulting services that address every facet of blood and plasma management. Haemonetics operates through three key segments: Plasma, Blood Center, and Hospital.
In the Plasma segment, Haemonetics focuses on providing innovative technologies for plasma collection and processing. The company's products help ensure a steady supply of high-quality plasma for the production of biopharmaceuticals and other therapeutic applications.
Within the Blood Center segment, Haemonetics offers advanced solutions for blood component collection and processing, aiding in the optimization of blood supply chains. Despite facing high competition in this segment, the company continues to innovate and enhance its product offerings.
The Hospital segment is a significant growth area for Haemonetics, providing essential tools for surgical suites and transfusion services. The company's technologies help prevent unnecessary blood transfusions and ensure the right blood product is used at the right time, improving patient outcomes.
Recently, Haemonetics has achieved several milestones, including the acquisition of Attune Medical, the manufacturer of the FDA-cleared ensoETM® esophageal cooling device. This acquisition strengthens Haemonetics' presence in the electrophysiology market and complements its vascular closure offerings.
Haemonetics also received 510(k) clearance from the U.S. FDA for the TEG® 6s hemostasis analyzer system Global Hemostasis-HN assay cartridge, expanding its capabilities to serve fully heparinized patients in critical surgical procedures.
The company's financial performance remains robust, with a strong focus on revenue growth and strategic investments. Haemonetics continues to explore new markets and develop cutting-edge technologies to stay at the forefront of the healthcare industry.
To stay updated with the latest developments and financial results, Haemonetics regularly hosts investor calls and webcasts, providing transparency and insights into its ongoing projects and future plans.
Haemonetics Corporation (NYSE: HAE) will host its Investor Day on June 29, 2022, in Boston, starting at 10:00 AM EDT. This hybrid event allows for in-person attendance for capital markets professionals, while others can participate via a webcast. Attendees can engage with product demonstrations before the presentations. The Company aims to update stakeholders on strategies, market leadership in plasma and hospital sectors, and plans for financial growth through fiscal 2026. A replay and presentation materials will be available post-event.
Haemonetics Corporation (NYSE: HAE) has made its fourth quarter fiscal 2022 financial results available online, following the period ending April 2, 2022. A conference call will be held on May 10, 2022, at 8:00 a.m. EDT to discuss these results. Investors can access the earnings release, analytical tables, and supplemental information on the Investor Relations website. The earnings call will also be available for replay for one year after the event.
Haemonetics Corporation (NYSE: HAE) will host an Investor Day on June 29, 2022, at 10:00 AM EDT in Boston. The event aims to share insights on the Company’s long-term strategic plans, key initiatives, and financial outlook. It will be hybrid, allowing in-person attendance and a simultaneous webcast for remote participants. Registration is required via the Company's Investor Relations website. A replay and presentation materials will be available post-event on Haemonetics' website.
Haemonetics Corporation (NYSE: HAE) will publish its fourth quarter and fiscal year 2022 financial results on May 10, 2022, at 6:00 am EDT. An investor conference call for discussing these results will be held at 8:00 am EDT on the same day. Investors can access the call by dialing (877) 848-8880 for U.S. and Canada or (716) 335-9512 internationally, with Conference ID 5347317. A live webcast will also be available through Haemonetics' investor relations website, with a replay accessible for one year post-call.
Haemonetics Corporation (NYSE: HAE) announced the appointment of James C. D'Arecca as Executive Vice President and Chief Financial Officer, effective April 11, 2022. D'Arecca succeeds William P. Burke, who will remain in an advisory role until June 30, 2022. D'Arecca brings nearly 30 years of experience in finance leadership from companies like TherapeuticsMD and Allergan. His role will include overseeing treasury, tax, and financial planning, critical for Haemonetics' growth objectives. The appointment aims to strengthen the financial strategy and enhance stakeholder value.
Haemonetics Corporation (NYSE: HAE) announced that CEO Chris Simon will engage in a fireside chat with investors at the Raymond James 43rd Annual Institutional Investors Conference on March 7, 2022, at 9:50 a.m. ET. Interested individuals can access a live webcast through Haemonetics' Investor Relations website, and a replay will be available 12 hours post-event for a year. Haemonetics focuses on innovative healthcare solutions to enhance patient care and reduce costs, particularly in blood and plasma collection, surgical operations, and transfusion services.
Haemonetics Corporation (NYSE: HAE) announced its third quarter fiscal 2022 financial results, concluding on January 1, 2022. The details are accessible on its Investor Relations website. A conference call will take place on February 8, 2022, at 8:00 a.m. EST to discuss these results, with a live webcast and replay available for a year. Haemonetics specializes in innovative medical products and solutions aimed at enhancing patient care and reducing healthcare costs across blood and plasma collection, surgical suites, and hospital transfusion services.
Haemonetics Corporation (NYSE: HAE) will release its third quarter fiscal year 2022 financial results on February 8, 2022, at 6:00 am EST. A conference call will be held at 8:00 am EST the same day, where executives will discuss the results and respond to questions. Investors can access the call via a toll-free number or participate through a live webcast on the company's investor relations website. A replay will be available for one year from the call's conclusion.
Haemonetics Corporation (NYSE: HAE) released its financial results for Q2 FY22, ending October 2, 2021. The results are now available on their Investor Relations website. A conference call is scheduled for November 9, 2021, at 8:00 a.m. EST to discuss these results, accessible via a toll-free number and a live webcast. The earnings release and analytical tables have been posted online for investor review. For more details, visit their website.
Haemonetics Corporation (NYSE: HAE) announced the upcoming retirement of CFO William P. Burke, effective June 30, 2022. Burke, who joined the company in 2016, will assist in the transition to his successor. CEO Chris Simon acknowledged Burke's significant contributions to the company’s turnaround and strategic financial initiatives that have fostered long-term growth. Burke expressed his pride in the company's finance team and confidence in Haemonetics' future direction.
FAQ
What is the current stock price of Haemonetics Corporation (HAE)?
What is the market cap of Haemonetics Corporation (HAE)?
What does Haemonetics Corporation specialize in?
What are the main segments of Haemonetics' business?
What recent acquisitions has Haemonetics made?
What is the TEG® 6s hemostasis analyzer system?
How does Haemonetics support its plasma segment?
What are the financial highlights of Haemonetics?
How does Haemonetics improve patient care?
What was the significance of the FDA clearance for Haemonetics?
What is Haemonetics' approach to innovation?
How can investors stay updated on Haemonetics' performance?
